Figure 1.
Increasing BMPR2 (bone morphogenetic protein receptor type 2) signaling may benefit both the lungs and the right ventricle (RV) in pulmonary arterial hypertension. Decreased BMPR2 signaling can contribute to both pulmonary vascular and RV disease, along with other potential pathologic stimuli, and targeting this pathway may therefore have dual beneficial effects in pulmonary arterial hypertension. The highlighted arrow is the focus of the present work by Boehm and colleagues (4).